Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 before and after BRAF Inhibition

Journal of Immunotherapy

Volumn 40, Issue 1, 2017, Pages 31-35

  Johnson, Douglas B ^a   Pectasides, Eirini ^b,c   Feld, Emily ^a   Ye, Fei ^a   Zhao, Shilin ^a   Johnpulle, Romany ^a   Merritt, Ryan ^d   McDermott, David F ^d   Puzanov, Igor ^a   Lawrence, Donald ^d   Sosman, Jeffrey A ^a   Buchbinder, Elizabeth ^c   Sullivany, Ryan J ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

anti PD 1; BRAF; dabrafenib; immune; melanoma; nivolumab; pembrolizumab; sequence; trametinib; vemurafenib

Indexed keywords

ATEZOLIZUMAB; B RAF KINASE INHIBITOR; BINIMETINIB; COBIMETINIB; DABRAFENIB; ENCORAFENIB; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BLOCKING ANTIBODY; BRAF PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX RATIO; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DNA SEQUENCE; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; MORTALITY; MULTICENTER STUDY; MUTATION; SURVIVAL ANALYSIS;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; COHORT STUDIES; CONTROLLED BEFORE-AFTER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IPILIMUMAB; MALE; MAP KINASE KINASE KINASES; MELANOMA; MIDDLE AGED; MUTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS;

EID: 85027920108     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000148     Document Type: Article

References (23)

1. Topalian SL, Hodi FS, B-hmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
2. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-144.
3. Robert C, Long GV, B-dy B, et al. Nivolumab in previously untreated melanoma without B-F mutation. N Engl J Med. 2015;372:320-330.
4. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemothe-py for ipilimumab-ref-ctory melanoma (KEYNOTE-002): a-ndomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908-918.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemu-fenib in melanoma with B-F V600E mutation. N Engl J Med. 2011;364:2507-2516.
6. Sosman JA, Kim KB, Schuchter L, et al. Survival in B-F V600-mutant advanced melanoma treated with vemu-fenib. N Engl J Med. 2012;366:707-714.
7. Hauschild A, Grob JJ, Demidov LV, et al. Dab-fenib in B-F-mutated metastatic melanoma: a multicentre, openlabel, phase 3-ndomised controlled trial. Lancet. 2012;380: 358-365.
8. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monothe-py in untreated melanoma. N Engl J Med. 2015;373:23-34.
9. Long GV, Stroyakovskiy D, Gogas H, et al. Dab-fenib and t-metinib versus dab-fenib and placebo for Val600 B-Fmutant melanoma: a multicentre, double-blind, phase 3-ndomised controlled trial. Lancet. 2015;386:444-451.
10. Long GV, Weber JS, Infante JR, et al. Ove-ll survival and du-ble responses in patients with B-F V600-mutant metastatic melanoma receiving dab-fenib combined with t-metinib. J Clin Oncol. 2016;34:871-878.
11. Ackerman A, McDermott DF, Lawrence DP, et al. Outcomes of patients with malignant melanoma treated with immunothe-py prior to or after vemu-fenib. J Clin Oncol. 2012; 30:8569.
12. Ascierto PA, Simeone E, Giannarelli D, et al. Sequencing of B-F inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J T-nsl Med. 2012;10:107.
13. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372: 2521-2532.
14. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.
15. Long GV, Stroyakovskiy D, Gogas H, et al. Combined B-F and MEK Inhibition versus B-F inhibition alone in melanoma. Lancet. 2015;386:444-451.
16. Robert C, Ka-szewska B, Schachter J, et al. Improved ove-ll survival in melanoma with combined dab-fenib and t-metinib. N Engl J Med. 2015;372:30-39.
17. Larkin J, Ascierto PA, Dreno B, et al. Combined vemu-fenib and cobimetinib in B-F-mutated melanoma. N Engl J Med. 2014;371:1867-1876.
18. Larkin J, Lao CD, Urba WJ, et al. Efficacy and safety of nivolumab in patients with B-F V600 mutant and b-f wildtype advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1:433-440.
19. Manujam S, Lo S, Kong B, et al. Anti-PD1 responses in B-F mutated advanced melanoma patients with prior B-F inhibitor (B-Fi) or combined B-F and MEK inhibitor (Combi) the-py. Pigment Cell Melanoma Res. 2015. [Abst-ct].
20. Puzanov I, Ribas A, Daud A, et al. Pembrolizumab for advanced melanoma: effect of B-FV600 mutation status and prior B-F inhibitor the-py. Pigment Cell Melanoma Res. 2015. [Abst-ct].
21. Eisenhauer EA, The-sse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer. 2009;45:228-247.
22. Hugo W, Zaretsky JM, Sun L, et al. Genomic and t-nscriptomic features of response to anti-PD-1 the-py in metastatic melanoma. Cell. 2016;165:35-44.
23. Hugo W, Shi H, Sun L, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015;162:1271-1285.